B

    BioAge Labs, Inc (BIOA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $9.50
    -0.15 (-1.55%)

    Market Cap: $442.90M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(3/8)
    Avg Surprise
    -109.53%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.61
    Range$-0.69 - $-0.42
    7 analysts
    EPS Revisions
    3
    0
    7d
    2
    1
    30d
    EPS Estimate Drift
    90d ago$-0.61+0.0%
    60d ago$-0.66-8.0%
    30d ago$-0.66-8.0%
    7d ago$-0.65-7.4%
    Current$-0.61
    Revenue Consensus
    $2M
    Range$0 - $3M
    9 analysts
    Dec 31, 2026
    EPS Consensus$-0.51
    Range$-0.91 - $-0.08
    7 analysts
    Revenue Consensus
    $4M
    Range$1M - $6M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.51---
    Sep 26EST
    		-$-0.61---
    Jun 26
    		$-0.58$-0.65+10.77%Beat+3.3%
    Mar 26
    		$-0.52$-0.71+26.76%Beat-44.4%
    Dec 25
    		$-0.72$-0.67-7.69%Miss+28.0%
    Sep 25
    		$-0.56$-0.51-9.80%Miss+91.6%
    Jun 25
    		$-0.60$-0.38-57.89%Miss+0.0%
    Mar 25
    		$-0.36$-0.53+32.08%Beat-
    Dec 24
    		$-1.00$-0.66-52.67%Miss-
    Sep 24
    		$-6.70$-0.73-817.81%Miss-
    Jun 24
    		$-0.60$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.99EV/EBITDAN/A
    Price/FCF-4.84xFCF Yield-20.68%
    Profitability
    Profit Margin0.00%Operating Margin-1197.00%
    ROE-28.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-378.19x
    Current Ratio17.19xQuick Ratio17.19x
    Trading Statistics
    BetaN/AAvg Volume866.63K
    52-Week High$25.9552-Week Low$4.55

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$9.89
    SMA 20$10.41
    SMA 50$17.49
    SMA 200$16.89
    EMA 10$10.06
    EMA 20$11.46
    EMA 50$14.79
    EMA 200$15.41

    MACD

    Line: -2.10Signal: -2.40Hist: 0.30

    ADX

    ADX: 37.4+DI: 15.3-DI: 35.8

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down16.0
    PSAR$19.29

    Bollinger Bands

    Upper Band$11.79
    Lower Band$9.02
    %B Position2658%(Upper)
    Band Width0.17

    RSI (14-Day)

    Neutral
    32.8

    Momentum Oscillators

    Stoch %K24.4
    Stoch %D27.1
    Williams %R-81.0
    ROC (10d)-8.7%
    Momentum-0.90
    CCI (20d)-125.0
    MFI (14d)23.8

    Volatility Measures

    ATR (14d)$1.06(11.2%)
    StdDev (20d)0.69
    Hist Vol63.3%(High)

    Volume Flow

    VWAP$9.44
    OBV4.7M
    AD Line7.5M
    CMF (20d)-0.013

    Volume Metrics

    Avg Vol (20d)733.3K
    Vol Ratio1.4x
    VWMA (20d)$10.55

    Pivot Points

    R3$10.72
    R2$10.49
    R1$10.07
    Pivot Point$9.83
    S1$9.41
    S2$9.18
    S3$8.76

    Advanced Oscillators

    TSI-35.23
    Ultimate Osc43.8
    KST-420.08

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$2.45M$2.77M$3.08M$2.05M$2.41M$1.45M$0$0$0$0$0$0
    Cost of Revenue$0$0$69,000$0$0$0N/A$0$0$0N/A$0
    Gross Profit$2.45M$2.77M$3.08M$2.05M$2.41M$1.45MN/A$0$0$0N/A$0
    Operating Expenses$31.78M$28.15M$31.50M$25.19M$27.18M$17.90M$25.36M$24.75M$15.27M$12.81M$13.60M$9.89M
    R&D$24.36M$20.41M$24.50M$18.51M$19.84M$11.11M$19.23M$20.02M$10.47M$9.32M$10.08M$6.53M
    SG&A$7.42M$7.74M$7.00M$6.68M$7.34M$6.79M$6.14M$4.73M$4.80M$3.49M$3.51M$3.35M
    Operating Income$-29,333,000$-25,375,000$-28,423,000$-23,140,000$-24,771,000$-16,446,000$-25,362,000$-24,750,000$-15,269,000$-12,813,000$-13,596,000$-9,887,000
    Interest Income$3.44M$3.27M$2.79M$3.16M$3.42M$3.71M$4.09M$2.04M$2.20M$1.30M$379,000$499,000
    Interest Expense$1,000$39,000$92,000$149,000$201,000$255,000$319,000$388,000$443,000$1.47M$2.56M$2.40M
    Income Before Tax$-25,896,000$-22,146,000$-25,723,000$-20,129,000$-21,552,000$-12,987,000$-21,280,000$-23,407,000$-13,511,000$-12,984,000$-20,958,000$-14,625,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-26,097,000$-22,253,000$-25,943,000$-20,171,000$-21,563,000$-12,928,000$-21,129,000$-23,407,000$-13,581,000$-12,992,000$-20,958,000$-14,625,000
    EBITDA$-29,826,000$-25,618,000$-28,354,000$-23,091,000$-24,713,000$-16,409,000$-25,315,000$-25,018,000$-15,220,000$-12,780,000$-18,358,000$-12,721,000
    EBIT$-29,333,000$-25,375,000$-28,423,000$-23,140,000$-24,771,000$-16,446,000$-25,362,000$-25,056,000$-15,269,000$-12,813,000$-18,399,000$-12,721,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BIOA

    News

    Bioage Labs Market Sentiment

    This article provides an overview of the market sentiment for Bioage Labs Inc. (BIOA), including analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from analysts with a significant potential upside in price targets, while also noting rising short interest and a bearish options flow. The report details recent analyst ratings and price target changes, indicating varying sentiments from different firms.

    Benzinga France•8/21/26•
    Neutral

    BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates

    BioAge Labs, Inc. (BIOA) reported a Q2 loss of $0.58 per share, surpassing the Zacks Consensus Estimate of a $0.65 loss, and beat revenue estimates with $2.45 million. Despite the positive earnings surprise, the company's shares have fallen 15.3% year-to-date, and it currently holds a Zacks Rank #4 (Sell), indicating potential underperformance in the near future.

    Eastern Progress•8/19/26•
    Neutral

    354,395 Shares in BioAge Labs, Inc. $BIOA Bought by Walleye Capital LLC

    Walleye Capital LLC recently acquired 354,395 shares of BioAge Labs, Inc. (NASDAQ:BIOA) for approximately $8.7 million, representing 0.8% of the company. Other institutional investors also increased their stakes in the clinical-stage biotech firm. Analysts have a "Moderate Buy" consensus rating with an average price target of $36.57, despite the company reporting a quarterly loss of $0.58 per share, which was narrower than expected.

    MarketBeat•8/15/26•
    Somewhat-Bullish

    Cormorant Asset Management (BIOA) discloses 5.38% BioAge Labs ownership stake

    Cormorant Asset Management, LP and Bihua Chen have disclosed a 5.38% beneficial ownership stake in BioAge Labs, Inc. (BIOA), as reported in an amended Schedule 13G filing. This ownership amounts to 2,390,605 shares of common stock, with both shared voting and dispositive power. The percentage is calculated based on 44,452,734 shares of BioAge Labs common stock outstanding as of May 1, 2026.

    Stock Titan•8/14/26•
    Neutral

    214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP

    Dimensional Fund Advisors LP acquired a new position in BioAge Labs, Inc. (NASDAQ:BIOA), purchasing 214,546 shares valued at approximately $3.75 million, representing a 0.48% stake in the company. Other institutional investors like Geode Capital and Marshall Wace also increased their holdings. Despite reporting a smaller-than-expected quarterly loss of $0.58 per share and generating $2.45 million in revenue, BioAge Labs remains unprofitable with a negative net margin of 912.26%, and its shares opened at $10.48, significantly below its 52-week high.

    MarketBeat•8/13/26•
    Neutral

    Frequently Asked Questions About BIOA

    Does BIOA pay dividends?
    BioAge Labs, Inc (BIOA) does not currently pay a regular dividend.
    What is BIOA's market cap?
    BioAge Labs, Inc (BIOA) has a market capitalization of $442.90M with a current stock price of $9.50.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In